Ravi Yang Sarin - 17 Mar 2023 Form 4 Insider Report for Oncology Institute, Inc. (TOI)

Reporting relationship: Director
Issuer ticker: TOI
Reported as of: 17 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Mar 2023, 20:52:18 UTC
Prior SEC filing: 21 Nov 2022
Next SEC filing: 20 Sep 2023
Source filing: View source filing
Reporting owner signature: /s/ Mark Hueppelsheuser, Attorney-in-Fact for Ravi Yang Sarin

Key filing fact

Ravi Yang Sarin filed Form 4 for Oncology Institute, Inc. (TOI) on 21 Mar 2023.

Key facts

This page summarizes Ravi Yang Sarin's Form 4 filing for Oncology Institute, Inc. (TOI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 Mar 2023, 20:52.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

Shares, units, or other non-derivative securities reported in this filing.

TOI transaction

Award

TOI holding

No transaction description listed

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

Represents restricted stock units that vest in full on March 16, 2024, subject to continued service with the Company through such vesting date.